Acid anhydrides, used in a number of industries, cause the immunotoxic response of allergy. The long term goal is to understand the mechanism of immunotoxicity of the acid anhydrides in the lung so rational therapeutic approaches can be designed. A guinea pig model of trimellitic anhydride (TMA)-induced allergy will be used because it mimics many symptoms seen in the allergic human. Animals will be sensitized ID with TMA and 3 wk later challenged intratracheally with antigen (TMA coupled to serum albumin). Components of the immunotoxic response to TMA which will be monitored include: broncho-constriction and an immediate decrease in circulating platelets; increased airway microvascular and pulmonary vascular permeability; lung hemorrhage; and eosinophil, neutrophil and mononuclear cell infiltration into the lung. The hypothesis is that TMA-GPSA combines with cytophilic IgG1 and/or non-cytophilic IgG2 Ab in the airspace and/or the circulation to cause complement activation with a resultant decrease in circulating platelets: both of which are required for the immunotoxic response to TMA. TMA- GPSA-specific IgG1 and IgG2 will be measured by ELISA in the serum and bronchoalveolar lavage (BAL) of actively-sensitized animals and correlated with the immunotoxic response. The ability of purified IgG1/IgG2 Ab to mediate the immunotoxic response will be determined in passively-sensitized animals. To determine which antibody mediates complement participation, animals will be passively sensitized with IgG1 or IgG2, depleted of complement with Cobra Venom Factor, and the response to TMA assessed. To determine if complement activation occurs in the circulation or airspace, complement cleavage product C3a will be assayed in plasma and BAL by a Western blot method. In vitro studies will determine combinations of antigen, Ab, and BAL cells which result in C3a generation or BAL cell activation. An isolated tracheal preparation will be used to determine if antigen movement (with or without Ab and C) is limited by epithelial permeability. The importance of platelets will be assessed by determining if platelets sequester in the lung and whether depleting platelets or preventing their aggregation affects the immunotoxic response. These studies will determine if cytophilic Ab can evoke participation of the complement system and if cytophilic plus non-cytophilic Ab can predict the immunotoxic response.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES007406-02
Application #
2459007
Study Section
Special Emphasis Panel (ZRG4-ALTX-2)
Project Start
1996-08-01
Project End
2000-07-31
Budget Start
1997-08-01
Budget End
1998-07-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pharmacology
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Larsen, Christen P; Regal, Jean F (2002) Trimellitic anhydride (TMA) dust induces airway obstruction and eosinophilia in non-sensitized guinea pigs. Toxicology 178:89-99
Larsen, Christen P; Regal, Jean F (2002) Trimellitic anhydride-induced cellular infiltration into Guinea pig lung varies with age but not gender. Int Arch Allergy Immunol 127:63-72
Larsen, C P; Regal, R R; Regal, J F (2001) Trimellitic anhydride-induced allergic response in the guinea pig lung involves antibody-dependent and -independent complement system activation. J Pharmacol Exp Ther 296:284-92
Regal, J F; Mohrman, M E; Sailstad, D M (2001) Trimellitic anhydride-induced eosinophilia in a mouse model of occupational asthma. Toxicol Appl Pharmacol 175:234-42
Regal, J F; Klos, A (2000) Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig. Immunopharmacology 46:15-28
Fraser, D G; Graziano, F M; Larsen, C P et al. (1998) The role of IgG1 and IgG2 in trimellitic anhydride-induced allergic response in the guinea pig lung. Toxicol Appl Pharmacol 150:218-27
Regal, J F (1997) Role of the complement system in pulmonary disorders. Immunopharmacology 38:17-25